Cargando…
Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
Hepatitis C virus (HCV) infection is responsible for both hepatic and extrahepatic manifestations. Before the era of direct-acting antivirals (DAA), cryoglobulinemia was related to HCV infection in 70–90% of cases. Observed in 30% to 40% of patients with hepatitis C, mixed cryoglobulinemia is mainly...
Autores principales: | Comarmond, Cloé, Cacoub, Patrice, Saadoun, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383649/ https://www.ncbi.nlm.nih.gov/pubmed/32782479 http://dx.doi.org/10.1177/1756284820942617 |
Ejemplares similares
-
Systemic vasculitis associated with vemurafenib treatment: Case report and literature review
por: Mirouse, Adrien, et al.
Publicado: (2016) -
Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals
por: Guo, Qianyu, et al.
Publicado: (2022) -
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
por: Saadoun, David, et al.
Publicado: (2014) -
New insights into HCV-related rheumatologic disorders: A review
por: Cacoub, Patrice, et al.
Publicado: (2017) -
The Spectrum of Type I Cryoglobulinemia Vasculitis: New Insights Based on 64 Cases
por: Terrier, Benjamin, et al.
Publicado: (2013)